Scarica l'app Stockscreener
1.27
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$1.27
Aprire:
$1.3
Volume 24 ore:
362.74K
Relative Volume:
0.36
Capitalizzazione di mercato:
$59.37M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-0.7651
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
+15.45%
1M Prestazione:
-23.49%
6M Prestazione:
-67.52%
1 anno Prestazione:
-89.57%
Intervallo 1D:
$1.23
$1.31
Intervallo di 1 settimana:
$1.08
$1.39
Portata 52W:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.27 | 59.37M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com
American Superconductor Corp (AMSC) requires closer examination - uspostnews.com
Aehr Test Systems (AEHR) shows promising results - uspostnews.com
Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Q1 EPS Estimate Increased by HC Wainwright - MarketBeat
William Blair Boosts Earnings Estimates for Cabaletta Bio - MarketBeat
William Blair Forecasts Cabaletta Bio Q1 Earnings - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company - MarketBeat
HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2025 Earnings - MarketBeat
UBS Group Issues Pessimistic Forecast for Cabaletta Bio (NASDAQ:CABA) Stock Price - MarketBeat
Thrivent Financial for Lutherans Buys New Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - Defense World
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at Guggenheim - MarketBeat
William Blair Increases Earnings Estimates for Cabaletta Bio - Defense World
Cabaletta Bio (NASDAQ:CABA) Issues Earnings Results, Meets Estimates - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - MarketBeat
William Blair Comments on Cabaletta Bio Q1 Earnings - Defense World
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN
Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World
FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline By Investing.com - Investing.com South Africa
Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat
Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - Defense World
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa
Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com
UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener
Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks
Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating - TipRanks
Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada
Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com
Cabaletta Bio Reports Wider Q4 Results As R&D Expenses Rise - Nasdaq
BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio, Inc. SEC 10-K Report - TradingView
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):